Nanomedicine and Bioengineering Research Laboratory, Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak 4848487, MP, India.
IPS Academy College of Pharmacy, A.B. Road, Rajendra Nagar, Indore (M.P.), India.
Curr Drug Targets. 2022;23(10):978-1001. doi: 10.2174/1389450123666220526155144.
Alzheimer's disease (AD) is a multifactorial, progressive, neurodegenerative disorder, manifested by the loss of memory and cognitive abilities, behavioral disturbance and progressive impairment of activities of daily life. The sharp rise in the number of AD patients has brought it within the top eight health issues in the world. It is associated with the distribution of misfolded aggregates of protein within the brain. However, Alois Alzheimer initially mentioned that the reduction in brain volume in AD might be associated with the "deposition of a special substance in the cortex". The resulting plaque found in extracellular space in the AD brain and hippocampus region, known as senile plaques, is the characteristic feature underlying Alzheimer's pathology, where the role of amyloid- β (Aβ) peptide formation from proteolytic cleavage of amyloid precursor protein (APP) by secretase enzyme is eminent. Therefore, this review has highlighted the molecular pathophysiology of AD with a variety of available diagnostic and treatment strategies for the management of the disease, with a focus on the advancement toward clinical research to provide new effective and safe tool in the diagnosis, treatment or management of AD.
阿尔茨海默病(AD)是一种多因素、进行性、神经退行性疾病,表现为记忆力和认知能力丧失、行为障碍和日常生活活动能力逐渐受损。AD 患者数量的急剧增加使其成为全球前八大健康问题之一。它与大脑内错误折叠的蛋白聚集体的分布有关。然而,Alois Alzheimer 最初提到 AD 中脑体积的减少可能与“皮质中特殊物质的沉积”有关。在 AD 大脑和海马区域的细胞外空间中发现的斑块,称为老年斑,是阿尔茨海默病病理学的特征,其中淀粉样蛋白-β(Aβ)肽由蛋白酶切割淀粉样前体蛋白(APP)形成的作用尤为明显。因此,本综述强调了 AD 的分子病理生理学,并介绍了各种现有的诊断和治疗策略来管理该疾病,重点是朝着临床研究的进展,为 AD 的诊断、治疗或管理提供新的有效和安全的工具。